Pembrolizumab: Nursing Drug Guide, Immune-Related Adverse Events & Hold Rules
Pembrolizumab unleashes T-cell activity against cancer—but the same mechanism can attack healthy tissue. Nurses must recognize immune-mediated pneumonitis, colitis, hepatitis, and endocrinopathies early, withhold or discontinue per grade, and escalate corticosteroids before attributing symptoms to disease progression alone.
Pembrolizumab can cause severe or fatal immune-mediated adverse reactions in any organ system. Keytruda labeling highlights pneumonitis, colitis, hepatitis, endocrinopathies (hypophysitis, thyroid disorders, type 1 diabetes), nephritis, and dermatologic, neurologic, and cardiac toxicities. Withhold pembrolizumab for Grade 3 irAEs and permanently discontinue for Grade 4 events per severity tables—dose reduction is not recommended. Monitor for new or worsening shortness of breath, diarrhea, transaminitis, or jaundice after every infusion and during outpatient follow-up.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before every pembrolizumab infusion, ask whether diarrhea, dyspnea, new rash, extreme fatigue, polyuria/polydipsia, or jaundice has developed since the last cycle—and hold the dose when a suspected Grade 3 irAE appears until the prescriber grades severity and starts corticosteroids. There is no dose reduction; management is hold, treat, and resume only when toxicity improves to Grade 0–1 per labeling.
Most common brand names
Pembrolizumab is marketed as Keytruda in the United States and internationally. It is a single-agent checkpoint inhibitor—not combined in one vial with chemotherapy—but patients often receive pembrolizumab alongside agents such as platinum doublets or fluorouracil-based regimens depending on indication; verify each drug on the MAR independently.
Confirm vial strength (100 mg/4 mL) and ordered schedule (200 mg every 3 weeks vs 400 mg every 6 weeks) at every infusion visit. Biosimilar substitution is not applicable to Keytruda at the time of this review; always match the ordered brand to the dispensed product.
Why we give it — Indications
Pembrolizumab is approved across multiple solid tumors and selected hematologic malignancies when PD-L1 expression, MSI-H/dMMR status, or tumor type meets labeling criteria. Oncology nurses most often administer it in infusion centers for lung cancer, melanoma, head and neck, bladder, and colon cancer (MSI-H/dMMR), among others per current Keytruda prescribing information.
| Use | Detail |
|---|---|
| NSCLC and other thoracic / GU tumors | Multiple NSCLC lines (including PD-L1–defined populations), HNSCC, urothelial carcinoma, and other solid tumors per tumor-type and biomarker criteria in labeling |
| Melanoma, MSI-H/dMMR, and additional indications | Advanced melanoma; MSI-H or dMMR solid tumors; HCC, RCC, endometrial, cervical, and other labeled malignancies with indication-specific dosing duration and combination regimens |
| Pediatric select uses | 2 mg/kg IV every 3 weeks (maximum 200 mg) for labeled pediatric indications—verify weight-based calculation and maximum cap each cycle |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Pembrolizumab is a humanized monoclonal IgG4 kappa antibody that binds to the PD-1 receptor and blocks interaction with PD-L1 and PD-L2 ligands. By releasing PD-1–mediated inhibition of T cells, it restores antitumor immune activity. The same immune activation can target normal tissues—producing immune-mediated pneumonitis, colitis, hepatitis, endocrinopathies, and other irAEs that nurses must distinguish from infection, progression, or chemotherapy toxicity.
Dosing overview
Verify the prescriber order against current Keytruda prescribing information. Dose reductions are not recommended for toxicity; management uses hold, corticosteroids, and permanent discontinuation per irAE grade.
Missed dose: Administer as soon as possible; maintain dosing interval—Keytruda labeling provides guidance on maintaining the schedule after delayed doses.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Onset (therapeutic) | Variable; tumor response may take weeks to months | Do not stop therapy for lack of early shrinkage alone; continue irAE surveillance throughout |
| Peak / exposure | Steady-state trough concentrations after repeated q3-week or q6-week dosing | irAEs may occur after any cycle—including late events months into therapy |
| Half-life | 22 days (elimination half-life per Keytruda labeling) | Immune effects and corticosteroid taper may extend beyond last dose; monitor after discontinuation |
| Duration | Fixed-duration or until progression/toxicity per indication | Hold rules apply at every infusion touchpoint even near planned treatment end |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Review interval history for new cough, dyspnea, diarrhea, rash, vision changes, polyuria, or fatigue since last cycle
- Confirm baseline and trend hepatic panel, thyroid function, glucose, and renal function per institutional immunotherapy protocol
- Verify no unresolved Grade ≥2 irAE from prior cycle; confirm corticosteroid taper status if recently treated for irAE
Contraindications
- Keytruda labeling lists none—but do not administer when a contraindicated unresolved irAE, active serious infection requiring hold, or prescriber hold order exists
- Permanently discontinue after life-threatening (Grade 4) immune-mediated reactions per labeling tables
Important interactions
| Drug / factor | Effect | Nursing action |
|---|---|---|
| Systemic corticosteroids / immunosuppressants | Used to treat irAEs; may affect antitumor activity if given chronically before pembrolizumab per labeling context | Coordinate prednisone or IV steroid orders with oncology; document taper and hold/resume timing on MAR |
| Other immune checkpoint inhibitors | Combination regimens increase irAE frequency and severity | Reconcile dual-checkpoint orders; intensify symptom monitoring and patient teaching |
| Autoimmune disease history | Increased risk of irAE flare; benefit-risk per prescriber | Document baseline disease status; lower threshold to hold and evaluate new symptoms |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: IV medication administration as an infusion over 30 minutes through a dedicated line per facility policy.
- Dilute to final concentration 1 to 10 mg/mL in 0.9% sodium chloride (NS) or 5% dextrose (D5W)—do not use other diluents
- Use an in-line or add-on 0.2 to 5 micron sterile, non-pyrogenic, low-protein-binding filter
- Inspect for particulates or discoloration; do not shake vials; administer as soon as compatible after preparation per labeling
Even when the bag is prepared and the line is accessed, stop if the patient reports Grade ≥2 new diarrhea, dyspnea, chest pain, jaundice, or prescriber hold order until oncology regrades toxicity and clears the cycle.
Expected therapeutic response
- Stable or improving disease on imaging (RECIST or iRECIST criteria per oncology)—response may be delayed
- Symptomatic improvement in tumor-related pain, dyspnea, or mass effect over weeks to months when effective
- Pseudo-progression may occur early—oncology interprets imaging; nurses continue irAE monitoring regardless
Red flags — Stop and act
Immune-mediated reactions can progress rapidly. Escalate when symptoms suggest organ inflammation—not uncomplicated chemotherapy nausea or mild viral illness.
- New or worsening dyspnea, cough, or chest pain—suspect immune-mediated pneumonitis; obtain urgent prescriber evaluation
- ≥6 stools/day above baseline, abdominal pain, blood or mucus in stool—immune-mediated colitis; hold pembrolizumab and notify prescriber same day
- Rising AST/ALT with jaundice, dark urine, or right upper quadrant pain—immune-mediated hepatitis
- Severe headache, vision changes, hypotension, or electrolyte abnormalities—hypophysitis or adrenal crisis
- Infusion-related reaction: rigors, hypotension, bronchospasm during or after infusion—stop infusion and treat per anaphylaxis protocol
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Fatigue, nausea, decreased appetite, rash, pruritus | Very common | Supportive care; differentiate mild symptoms from irAE—trend duration and severity |
| Immune-mediated pneumonitis | Serious; may be fatal | Hold/discontinue per grade; corticosteroids; urgent imaging and pulmonology/oncology escalation |
| Immune-mediated colitis / diarrhea | Serious | Hold per grade; stool workup; IV steroids for severe colitis; avoid attributing to diet alone |
| Immune-mediated hepatitis | Serious | Trend ALT/AST; hold and treat per labeling; permanently discontinue Grade 4 |
| Endocrinopathies (hypothyroidism, hyperthyroidism, hypophysitis, type 1 diabetes) | Serious; may be permanent | Monitor TSH and glucose; hormone replacement; endocrine referral |
| Fever with infusion reaction or irAE | Variable | Assess for infection vs immune toxicity; hold infusion; prescriber notification |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Keytruda prescribing information does not include a dedicated overdosage section. No specific antidote is listed.
Overdose management
- Management is supportive care and monitoring for adverse reactions or irAEs after supratherapeutic exposure
- Contact poison control or medical toxicology services per facility protocol and local guidance
- Intensify laboratory and symptom monitoring if accidental duplicate infusion occurs—document event and prescriber notification
Look-alike / sound-alike and error prevention
- Keytruda vs other checkpoint inhibitors—nivolumab (Opdivo), atezolizumab (Tecentriq), durvalumab (Imfinzi), ipilimumab (Yervoy); verify drug name on vial and MAR independently
- Schedule confusion—200 mg every 3 weeks vs 400 mg every 6 weeks; both are labeled adult regimens—do not interchange without prescriber order
- Dose vs mg/kg—pediatric weight-based orders require double-check with maximum 200 mg cap
- Filtration step—omitting 0.2–5 micron filter or wrong diluent concentration (must be 1–10 mg/mL) is a preparation error risk
- Attribution error—labeling irAE symptoms as chemotherapy-only toxicity delays hold and steroids
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Crush/split | Not applicable—IV infusion only |
| Food timing | Not applicable to IV route |
| Storage | Refrigerate vials per labeling; protect from light; prepared infusion stability per Keytruda and pharmacy guidance |
| Infusion time | 30 minutes—do not bolus; use pump or timed gravity per policy |
| Commonly missed | Skipping interval symptom review because patient “looks well”; assuming late-cycle diarrhea is always chemo-related |
| Ask pharmacy when | Diluent compatibility questions, filter supply, extended infusion hold times, or steroid premedication coordination |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Prior autoimmune disease (Crohn’s, RA, thyroiditis) | Higher irAE flare risk; prescriber benefit-risk assessment; lower threshold to hold and evaluate |
| Combination checkpoint or chemo-immunotherapy | Increased colitis, pneumonitis, and hepatic toxicity rates—enhanced monitoring and patient teaching |
| Organ transplant recipients | Rejection risk with PD-1 blockade—specialist oversight; generally not labeled for transplant populations |
| Pregnancy | Keytruda can cause fetal harm; verify pregnancy status before treatment; effective contraception during and after therapy per labeling |
| Lactation | Advise not to breastfeed during treatment and for duration specified in labeling due to potential serious adverse reactions in infant |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Interval symptoms: stool count, respiratory status, rash, oral intake, glucose, mental status
- Labs per protocol: LFTs, basic metabolic panel, TSH/free T4, glucose; additional tests when irAE suspected
- Imaging: chest X-ray or CT when pneumonitis suspected per prescriber
Document
- Pre-infusion symptom review, vital signs, and any hold action with prescriber notification
- Infusion start/stop times, filter use, dilution volume, and infusion-related reactions
- irAE grade, corticosteroid orders, and patient teaching on when to call before next cycle
Patient teaching
- Report new or worsening diarrhea, blood in stool, shortness of breath, cough, yellowing skin, extreme thirst, or frequent urination immediately—before the next infusion
- Do not start high-dose loperamide or withhold steroid instructions without calling the oncology team when severe diarrhea develops
- Carry wallet card listing pembrolizumab and emergency contact; inform all clinicians that you receive immunotherapy
- Understand therapy may be held—not dose-reduced—when immune toxicity occurs; corticosteroids treat the reaction
- Seek emergency care for severe dyspnea, chest pain, uncontrolled vomiting, or confusion per local emergency guidance
The Hold Rule
Do not give and contact the prescriber/oncology pharmacist when:
- Suspected Grade 3 immune-mediated adverse reaction (e.g., severe colitis, hepatitis, pneumonitis, endocrinopathy) until prescriber grades and initiates corticosteroids
- Any Grade 4 irAE—permanently discontinue pembrolizumab per labeling; do not resume
- Unresolved Grade 2 irAE that has not improved to Grade 0–1 with treatment
- Active prescriber hold order, significant infusion reaction, or preparation error (wrong dose, missing filter, particulate in bag)
- New significant LFT elevation, ≥6 stools/day above baseline, or SpO2 drop with respiratory symptoms pending oncology evaluation
Hold and resume parameters follow organ-specific tables in Keytruda labeling. Follow prescriber orders, pharmacy guidance, and institutional immunotherapy protocols.
Clinical practice integration and workflow
Oncology infusion nurses are the front line for irAE detection. Build a structured symptom review into every pembrolizumab visit—before premedication, before port access, and before starting the infusion.
1. Check-before-you-give protocol
- Right patient, drug (Keytruda), dose (200 mg vs 400 mg schedule), route, and cycle number
- Interval symptom screen: GI, pulmonary, hepatic, endocrine, dermatologic, neurologic
- Review trend labs and pending hold orders; complete medication reconciliation for steroids and supportive meds
- Confirm dilution, filter, and 30-minute infusion setup with pharmacy-prepared or bedside-prepared bag per policy
2. High-alert and safety badge
Immunotherapy high-risk agent — irAE surveillance required every cycleTreat pembrolizumab with checkpoint-inhibitor safety rigor: independent symptom grading, hold documentation, and corticosteroid coordination even when the patient appears stable.
3. Clinical workflow: hold and question rules
- Grade ≥3 suspected irAE: hold infusion or next scheduled dose; notify prescriber same day; initiate workup and steroids per protocol
- Grade 4 irAE: permanently discontinue; escalate to appropriate specialty; document discontinuation in MAR and care plan
- Worsening LFTs or stool count between cycles: telephone triage same day—do not wait for next scheduled appointment
4. Critical teach-back questions
- “What new symptoms should you report before your next Keytruda infusion?” (Patient should name diarrhea, breathing changes, jaundice, severe fatigue, vision changes, or excessive thirst—and state they will call before the next dose.)
- “If you have severe diarrhea, should you take extra antidiarrheal medicine and keep your infusion appointment without calling?” (Patient should say no—call the oncology team first because immune colitis may require hold and steroids, not antidiarrheals alone.)
5. Care coordination
Prescriber / oncology:: Grade irAEs, hold vs resume timing, imaging, and steroid taper plans
Pharmacist:: Dilution/filter verification, drug interaction checks with corticosteroids, and MAR accuracy for q3-week vs q6-week schedules
🧠 Quick mental checklist
- Any new diarrhea, dyspnea, rash, jaundice, or endocrine symptoms since last cycle?
- Are LFTs, TSH, and glucose trended—and any Grade ≥2 values unresolved?
- Is there a prescriber hold order or active corticosteroid taper on the MAR?
- Correct schedule (200 mg q3 weeks vs 400 mg q6 weeks), filter, and 30-minute infusion time?
- Patient knows to call before next infusion if symptoms worsen—not just at appointment?
Pembrolizumab NCLEX practice questions
Rehearse NCLEX-style clinical judgment practice for pembrolizumab immune-related adverse event safety using a tabbed oncology case (MAR, labs, vitals, nursing notes), then priority action, cue recognition (SATA), lab/symptom trend interpretation, irAE documentation cloze, ordered escalation, and matrix urgency sorting—recognise cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Pembrolizumab (Keytruda) 200 mg IV every 3 weeks — cycle 4 due today; last infusion 19 days ago
- Ondansetron 8 mg IV PRN nausea — given prior cycle only
- Loperamide 2 mg PO PRN diarrhea — patient self-administered extra doses this week
- No corticosteroid on MAR; oncology note: NSCLC on pembrolizumab monotherapy
- AST today: 186 U/L (baseline 4 weeks ago 42 U/L); ALT 98 U/L (was 38)
- Total bilirubin 1.4 mg/dL; alkaline phosphatase 142 U/L
- TSH 2.1 mIU/L; glucose 118 mg/dL; creatinine 0.9 mg/dL
- CBC: WBC 6.2 × 109/L; hemoglobin 12.4 g/dL
- Temp 37.2 °C; HR 88; BP 118/76; RR 16; SpO2 97% on room air
- Weight down 1.5 kg since last visit; mucous membranes slightly dry
- Lung auscultation clear; no supplemental oxygen
- 0630: Patient reports 6–8 watery stools/day × 5 days with cramping; denies hematochezia yesterday
- 0645: Nurse notified oncology NP; pembrolizumab infusion held pending evaluation
- 0700: Stool studies and repeat LFTs ordered; patient asks if extra loperamide is enough to keep today’s infusion
- Teaching gap: patient thought diarrhea was “normal chemo side effect” though on immunotherapy alone
Answer key & rationale
Frequently asked questions
When should a nurse hold pembrolizumab for an immune-related adverse event?
Keytruda labeling directs withholding pembrolizumab for Grade 3 immune-mediated adverse reactions and permanently discontinuing for Grade 4 events. Hold when new or worsening pneumonitis, colitis, hepatitis, endocrinopathy, nephritis, or other suspected irAE appears until the prescriber evaluates severity and initiates corticosteroids per protocol.
What symptoms suggest immune-mediated colitis on pembrolizumab?
Labeling lists diarrhea or colitis as immune-mediated adverse reactions. Nurses should escalate when watery stools increase in frequency, abdominal pain or cramping worsens, blood or mucus appears in stool, or dehydration develops—especially after recent infusion. Do not attribute worsening GI symptoms to chemotherapy alone without irAE evaluation.
Can pembrolizumab dose be reduced for toxicity?
No. Keytruda prescribing information states dose reductions are not recommended. Management of toxicity is withholding or permanently discontinuing pembrolizumab and treating with corticosteroids or other immunosuppression per the severity-based tables in the label—not lowering the mg dose.
How is pembrolizumab administered?
Administer as an IV infusion over 30 minutes. Adults receive 200 mg every 3 weeks or 400 mg every 6 weeks. Dilute to final concentration 1 to 10 mg/mL in 0.9% sodium chloride or 5% dextrose and use an in-line or add-on 0.2 to 5 micron filter per labeling.
What labs should nurses trend for immune-related hepatitis on pembrolizumab?
Monitor hepatic transaminases and bilirubin per protocol. Keytruda labeling includes immune-mediated hepatitis with management based on AST/ALT and total bilirubin grades. Trend ALT and AST with bilirubin when the patient reports fatigue, nausea, right upper quadrant pain, or jaundice during or after therapy.
Is there a specific antidote for pembrolizumab overdose?
Keytruda labeling does not include a dedicated overdosage section. No specific antidote is listed. Management is supportive care and monitoring for adverse reactions; contact poison control or medical toxicology services per facility protocol and local guidance.
References
-
U.S. National Library of Medicine. KEYTRUDA (pembrolizumab) injection — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9333c79b-d487-4538-a9f0-71b91a02b287
-
U.S. Food and Drug Administration. Keytruda (pembrolizumab) prescribing information label PDF.https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/125514s188lbl.pdf
-
National Comprehensive Cancer Network. NCCN Guidelines — Management of Immunotherapy-Related Toxicities.https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1485
-
Institute for Safe Medication Practices. ISMP List of High-Alert Medications in Acute Care Settings.https://www.ismp.org/recommendations/high-alert-medications-acute-list
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.